Skip to content
Technology Opportunities & Ventures
While focus is on header menu items,
press the down arrow to open sub-menu.

For Innovators

Getting your innovations out into the world and to the people that need them.

In This Section

‹ Home › Startups › Our Startup Portfolio › Aethon Therapeutics

Startups

Aethon Therapeutics

Aethon Therapeutics

2022
Active

Principal Investigators: Ben Neal, PhD/Shohei Koide, PhD

Aethon takes a novel approach to fighting cancer, creating custom antibody therapeutics that unite immunotherapy and targeted therapy. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations. Aethon Therapeutics’ focus is on developing therapies that target mitochondrial metabolism, which is known to play a critical role in cancer cell survival and drug resistance.